Anemia occurs in 30–90% of cancer patients depending on tumor type and treatment phase, making it one of the most common hematologic complications in oncology. For medical professionals, the connection between anemia and cancer is clinically significant in two directions: anemia can be the first presenting sign of an occult malignancy, and cancer itself (or its treatment) frequently causes anemia through multiple overlapping mechanisms.
So does anemia mean cancer? No — the vast majority of anemia cases are benign, caused by iron deficiency, chronic kidney disease, or nutritional deficits. But unexplained anemia, particularly in patients over 50 with iron-deficiency anemia and no obvious source of blood loss, should trigger a workup that includes malignancy on the differential. A 2023 study in Blood Advances found that approximately 6–15% of patients with unexplained iron-deficiency anemia were ultimately diagnosed with a GI malignancy.
How Cancer Directly Causes Anemia
Cancer drives anemia through several distinct pathways, and clinicians need to identify which mechanism is at play because treatment differs for each one.
Bone Marrow Infiltration
Hematologic malignancies like leukemia, lymphoma, and multiple myeloma directly invade the bone marrow, crowding out normal erythroid precursors. Metastatic solid tumors — particularly breast, prostate, and lung — can also seed the marrow. A peripheral smear showing leukoerythroblastic changes (nucleated RBCs, teardrop cells, immature granulocytes) is a classic red flag for marrow infiltration.
Anemia of Chronic Disease (ACD)
This is the single most common cause of anemia in cancer patients. Tumor-associated inflammation drives elevated hepcidin, which blocks iron absorption from the gut and traps iron inside macrophages. The result: functionally low iron despite adequate or even elevated ferritin stores. Hemoglobin typically hovers between 8–10 g/dL, and the anemia is normocytic or mildly microcytic.
Blood Loss
GI malignancies (colon, gastric, esophageal) cause chronic occult bleeding that depletes iron stores over months. Any patient over 40 with new iron-deficiency anemia and a ferritin below 20 ng/mL deserves colonoscopy and upper endoscopy — full stop.
Hemolysis
Autoimmune hemolytic anemia occurs in roughly 5–10% of CLL patients and can also accompany lymphomas. Microangiopathic hemolytic anemia (MAHA) with schistocytes on smear may signal disseminated mucin-secreting adenocarcinomas, particularly gastric cancer.
Treatment-Related Anemia
Cancer treatment itself is a major driver of anemia, and its severity often dictates dose modifications and treatment delays.
| Treatment | Mechanism of Anemia | Typical Onset | Severity |
|---|---|---|---|
| Platinum-based chemo (cisplatin, carboplatin) | Myelosuppression + renal EPO suppression | Weeks 2–4 per cycle | Moderate to severe |
| Radiation (pelvis, spine, long bones) | Direct marrow damage | Weeks 3–6 | Mild to moderate |
| Immunotherapy (checkpoint inhibitors) | Autoimmune hemolysis (rare) | Variable | Can be severe |
| Targeted therapy (ibrutinib, lenalidomide) | Myelosuppression | First 1–3 months | Mild to moderate |
Diagnostic Approach: Distinguishing the Cause
The key challenge is differentiating iron-deficiency anemia (IDA) from anemia of chronic disease (ACD), since they coexist in up to 40% of cancer patients. Standard iron studies alone can mislead you.
| Lab Marker | IDA | ACD | Mixed IDA + ACD |
|---|---|---|---|
| Ferritin | <15 ng/mL | 30–500 ng/mL | 15–100 ng/mL |
| TIBC | Elevated (>400 µg/dL) | Low to normal | Variable |
| Transferrin saturation | <16% | <20% | <20% |
| Soluble transferrin receptor (sTfR) | Elevated | Normal | Elevated |
| sTfR/log ferritin ratio | >2 | <1 | 1–2 |
| Hepcidin | Low | Elevated | Variable |
The soluble transferrin receptor (sTfR) and the sTfR/log ferritin index are particularly useful when ferritin is in the ambiguous 30–100 ng/mL range. A ratio greater than 2 strongly suggests true iron deficiency coexisting with inflammation.
When to Order a Bone Marrow Biopsy
Reserve marrow biopsy for cases with unexplained cytopenias (not just isolated anemia), leukoerythroblastic blood smear, suspected hematologic malignancy, or anemia unresponsive to iron/B12/folate replacement. It remains the gold standard for diagnosing marrow infiltration and myelodysplastic syndromes.
Management Strategies in Oncology Patients
Treatment depends on the underlying mechanism, severity, and the patient’s symptom burden.
- IV iron — First-line for functional or absolute iron deficiency in cancer patients. Oral iron is poorly absorbed in the setting of elevated hepcidin. IV ferric carboxymaltose or iron sucrose are preferred.
- Erythropoiesis-stimulating agents (ESAs) — Consider for chemotherapy-induced anemia when Hgb drops below 10 g/dL. Target a hemoglobin of 10–12 g/dL; exceeding 12 g/dL increases thromboembolic risk. ESAs are contraindicated in patients receiving curative-intent chemotherapy per ASCO/ASH guidelines due to concerns about tumor progression.
- Red blood cell transfusion — Reserved for symptomatic anemia or Hgb below 7–8 g/dL. Use a restrictive transfusion threshold in hemodynamically stable patients.
- Treat the underlying malignancy — Often the most effective long-term strategy. Anemia frequently improves as tumor burden decreases.
Red Flags: When Anemia Should Prompt a Cancer Workup
Not every anemia needs a malignancy evaluation. But the following scenarios should raise your index of suspicion:
- New iron-deficiency anemia in any patient over age 50 (or postmenopausal women of any age) without an obvious bleeding source
- Unexplained anemia with weight loss, night sweats, or lymphadenopathy
- Progressive anemia that fails to respond to appropriate iron, B12, or folate supplementation
- Peripheral smear showing leukoerythroblastic changes, schistocytes, or rouleaux formation
- Markedly elevated ESR or LDH with unexplained anemia
Frequently Asked Questions
Does anemia always indicate cancer?
No. The overwhelming majority of anemia cases are caused by iron deficiency, chronic disease, or nutritional deficits — not cancer. However, new unexplained anemia in older adults warrants investigation to rule out malignancy, especially GI cancers.
What hemoglobin level is concerning for cancer?
There’s no single hemoglobin cutoff that points specifically to cancer. That said, an unexplained hemoglobin drop below 10 g/dL in an older adult, especially with microcytosis and low ferritin, should prompt colonoscopy and further evaluation. The pattern and context matter more than the absolute number.
Can cancer treatment cure the anemia?
Often, yes. If the anemia is caused by the tumor itself — through chronic blood loss, marrow infiltration, or inflammatory cytokines — successful treatment of the cancer frequently resolves the anemia. However, chemotherapy-induced anemia may persist for weeks to months after treatment ends.
Should ESAs be used in all cancer patients with anemia?
No. Current ASCO/ASH guidelines restrict ESA use to patients receiving palliative-intent chemotherapy with hemoglobin below 10 g/dL. ESAs carry risks of thromboembolism and potential tumor stimulation and should not be used when the treatment goal is curative.
What’s the most overlooked cause of anemia in cancer patients?
Coexisting true iron deficiency in patients already labeled as having “anemia of chronic disease.” Studies show that up to 40% of cancer patients with ACD also have concurrent iron deficiency, which is treatable with IV iron. Checking sTfR or the sTfR/log ferritin ratio can unmask this overlap.
Key Takeaways for Clinicians
- Anemia in cancer is multifactorial — always consider overlapping mechanisms rather than settling on a single cause.
- Ferritin alone is unreliable in cancer patients due to inflammation. Use sTfR and transferrin saturation together for a clearer picture.
- IV iron is underutilized in oncology; it improves hemoglobin and can reduce transfusion requirements by 20–40%.
- Every new case of unexplained iron-deficiency anemia in a patient over 50 deserves GI evaluation — this remains one of the most reliable early signals of colorectal cancer.
- Anemia severity independently predicts worse outcomes in cancer — managing it aggressively improves quality of life and may improve treatment tolerance.
